Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial

Fineline Cube May 6, 2025

China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...

Company Drug

Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial

Fineline Cube Apr 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...

Company

Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025

Fineline Cube Apr 30, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1...

Company Deals

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Fineline Cube Apr 30, 2025

France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...

Company

Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands

Fineline Cube Apr 30, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...

Company

Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware

Fineline Cube Apr 30, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...

Company Deals

Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies

Fineline Cube Apr 30, 2025

Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a...

Company Drug

AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis

Fineline Cube Apr 30, 2025

US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...

Company Drug

Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma

Fineline Cube Apr 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...

Company Deals

Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems

Fineline Cube Apr 30, 2025

Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...

Company Deals

Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...

Company

Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...

Company Medical Device

Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation

Fineline Cube Apr 30, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its VENTANA TROP2 (EPR20043) RxDx...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV

Fineline Cube Apr 30, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...

Company Deals

Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar

Fineline Cube Apr 30, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...

Legal / IP

BeiGene Wins USPTO Ruling Invalidating Pharmacyclics’ Patent Claims

Fineline Cube Apr 30, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company

AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines

Fineline Cube Apr 30, 2025

UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...

Company

Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact

Fineline Cube Apr 30, 2025

US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...

Company

United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials

Fineline Cube Apr 29, 2025

China-based device giant United Imaging Healthcare (UIH, SHA: 688271) released its 2024 financial report, recording...

Company Deals

Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma

Fineline Cube Apr 29, 2025

China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...

Posts pagination

1 … 200 201 202 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.